NFX.L
Nuformix plc [NFX.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NFX.L Stock Summary
Top 10 Correlated ETFs
NFX.L
Top 10 Correlated Stocks
NFX.L
In the News
NFX.L Financial details
Company Rating
-
Market Cap
1.57M
Income
-1.23M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
30 Jun 2024
P/E
-3.27
Forward P/E
-
PEG
-1.04
P/S
-
P/B
0.59
P/C
-
P/FCF
-7.13
Quick Ratio
0.95
Current Ratio
1.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-57.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-25.98%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-40%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-17%
ROC
-0.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.18-0.44
52W High
-
52W Low
-
RSI
61
Rel Volume
58.2
Avg Volume
2.44M
Volume
141.72M
Perf Week
9.43%
Perf Month
75.76%
Perf Quarter
176.19%
Perf Half Y
132%
-
-
-
-
Beta
0.286
-
-
Volatility
0.01%, 0.02%
Prev Close
7.41%
Price
0.145
Change
3.57%
Company Profile
- Volume Average 2.44M
- Market Capitalization 1.57M
- Employee 3
- CEO Dr. Daniel John Gooding
- Headquarters London,GB
- IPO Date 2015-12-17
-
Website
https://www.nuformix.com 
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
